183.61
+0.05(+0.03%)
Currency In USD
| Previous Close | 183.56 |
| Open | 181.48 |
| Day High | 187.75 |
| Day Low | 181.48 |
| 52-Week High | 206.71 |
| 52-Week Low | 26.7 |
| Volume | 433,113 |
| Average Volume | 801,725 |
| Market Cap | 3.88B |
| PE | -14.15 |
| EPS | -12.98 |
| Moving Average 50 Days | 98.8 |
| Moving Average 200 Days | 60.34 |
| Change | 0.05 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $440.31 as of November 13, 2025 at a share price of $183.61. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 3 years ago, it would be worth $5,746.79 as of November 13, 2025 at a share price of $183.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 05, 2025 9:01 PM GMT
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy Designation Key aspects of a potential NDA application discussed and aligned with the Agency Praxis plans to perform an interim analysis of the EMBOLD cohort 2 p
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
GlobeNewswire Inc.
Oct 17, 2025 3:45 AM GMT
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characte